<?xml version="1.0" encoding="UTF-8"?><ns2:project xmlns:ns1="http://gtr.rcuk.ac.uk/gtr/api" xmlns:ns2="http://gtr.rcuk.ac.uk/gtr/api/project" xmlns:ns3="http://gtr.rcuk.ac.uk/gtr/api/fund" xmlns:ns4="http://gtr.rcuk.ac.uk/gtr/api/person" xmlns:ns5="http://gtr.rcuk.ac.uk/gtr/api/project/outcome" xmlns:ns6="http://gtr.rcuk.ac.uk/gtr/api/organisation" ns1:created="2026-07-08T08:44:08Z" ns1:href="http://gtr.ukri.org/gtr/api/projects/1D7E7034-E2F9-4639-B5AD-1DDE76910B63" ns1:id="1D7E7034-E2F9-4639-B5AD-1DDE76910B63"><ns1:links><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/persons/89ACBB0C-F7D2-4422-AD0E-C908F3324635" ns1:rel="PM_PER"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/6E8B95DA-74BD-4671-835F-6330D17493FC" ns1:rel="LEAD_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/6E8B95DA-74BD-4671-835F-6330D17493FC" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:end="2021-07-30T23:00:00Z" ns1:href="http://gtr.ukri.org/gtr/api/funds/081E30C5-5982-432F-A3B7-DC7BF24EC6F0" ns1:rel="FUND" ns1:start="2020-11-01T00:00:00Z"/></ns1:links><ns2:identifiers><ns2:identifier ns2:type="RCUK">88249</ns2:identifier></ns2:identifiers><ns2:title>Development of a novel, cost-effective, platform-based cell-sorting solution superior to current best-in-class</ns2:title><ns2:status>Closed</ns2:status><ns2:grantCategory>Collaborative R&amp;D</ns2:grantCategory><ns2:leadFunder>Innovate UK</ns2:leadFunder><ns2:abstractText>Founded by Dr Chris Wood (Associate Professor of High-Frequency and Mesoscopic Electronics), Christoph W&amp;auml;lti (Professor of Bionanotechnology) and Jennifer Kirkham (Professor of Oral Biology), Cell Lane (CL) is a growing UK-based SME specialising in cell-separation technologies to support next generation, regenerative cell therapies. Current cell-separation technologies are either inefficient, costly or introduce impurities, thereby slowing the advancement of cell therapies to treat a range of injuries and disease including cancer, Parkinson's disease, diabetes and stroke. CL aims to provide a novel, cost-effective, platform-based, cell-sorting solution superior to current best-in-class technologies. CL proposes a year-5 post-project revenue of &amp;pound;4.6M--6.2M.</ns2:abstractText></ns2:project>